NCT00000178已完成3 期
Multicenter Trial of Prednisone in Alzheimer's Disease
National Institute on Aging (NIA)19 个研究点 分布在 1 个国家开始时间: 1999年11月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 试验地点
- 19
研究概览
简要总结
This is a randomized placebo controlled, double blind study. Patients who meet eligibility criteria and decide to participate in the study will be randomly assigned to receive either drug treatment or a placebo. Neither the patients nor the participating investigators will know who is receiving the drugs and who is receiving the placebo. Participation involves 15 outpatient clinic visits over a 68 week period. Patients take study medication at varying doses (the maximum dose is 20 mg daily), along with calcium and vitamin supplements.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 0 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with Alzheimer's disease who are in stable medical condition
排除标准
- •Patients with diabetes or severe osteoporosis
研究者
研究点 (19)
Loading locations...
相似试验
Unknown
3 期
Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) PatientsHepatocellular,CarcinomaNCT01489566Shenzhen Kangzhe Pharmaceutical Co., Ltd.300
已完成
4 期
Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)Non-small Cell Lung Cancer (NSCLC)NCT00770588AstraZeneca296
Unknown
3 期
Expanding Phase III Study of Tyroserleutide for InjectionHepatocellular CarcinomaNCT03516448Shenzhen Kangzhe Pharmaceutical Co., Ltd.352
已完成
2 期
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque PsoriasisPlaque PsoriasisNCT05600036Alumis Inc228
已完成
3 期
RCT for Pregabalin in Restless Legs Syndrome in South KoreaRestless Legs SyndromeNCT04161027Seoul National University Hospital116